Evolent Health (NYSE:EVH) Full Year 2023 Results
Main financial results
-
Revenue: USD 1.96 billion (45% increase from 2022).
-
Net loss: USD 142.3 million (loss increased by USD 123.6 million from FY2022).
-
Loss of US$1.28 per share (worsening from loss of US$0.20 in FY22).
All numbers shown in the chart above are for the trailing 12 month (TTM) period.
Evolol Health EPS disappoints
Sales were in line with analyst forecasts. Earnings per share (EPS) were 22% lower than analysts expected.
Looking ahead, revenue is expected to grow at an average annual rate of 14% over the next three years, compared to an 11% growth forecast for the U.S. healthcare services industry.
performance of American healthcare services industry.
The company’s stock price has increased 10% from a week ago.
risk analysis
What we discovered is remarkable 2 warning signs for Evolent Health Things you need to consider.
Have feedback on this article? Curious about its content? contact Please contact us directly. Alternatively, email our editorial team at Simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.
